These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1427553)

  • 1. [Physical therapy and speech therapy in Parkinson syndrome--a status assessment].
    Vieregge P; Dethlefsen J
    Fortschr Neurol Psychiatr; 1992 Oct; 60(10):369-74. PubMed ID: 1427553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Medical management and social status of elderly Parkinson patients].
    Vieregge P; Körtke D; Meyer-Bornsen C
    Z Gerontol; 1994; 27(4):260-9. PubMed ID: 7975817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Parkinson disease and neurologic rehabilitation].
    Auff E; Fertl E; Schnider P
    Wien Med Wochenschr; 1995; 145(13):302-5. PubMed ID: 7571656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Depressive pseudodementia in early Parkinson's disease: lessons from a case with long-term follow-up].
    Giménez-Roldán S; Mateo D; Dobato JL
    Neurologia; 1997 Mar; 12(3):130-5. PubMed ID: 9198454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.
    Tison F; Yekhlef F; Chrysostome V; Balestre E; Quinn NP; Poewe W; Wenning GK
    Mov Disord; 2002 Jul; 17(4):701-9. PubMed ID: 12210859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of disability and quality of life in mild to moderate Parkinson disease.
    Muslimovic D; Post B; Speelman JD; Schmand B; de Haan RJ;
    Neurology; 2008 Jun; 70(23):2241-7. PubMed ID: 18519873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
    Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
    J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Frontal dementia or dementia praecox? A case report of a psychotic disorder with a severe decline].
    Vanderzeypen F; Bier JC; Genevrois C; Mendlewicz J; Lotstra F
    Encephale; 2003; 29(2):172-80. PubMed ID: 14567169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of motor impairment and disability in Parkinson disease: a population-based study.
    Alves G; Wentzel-Larsen T; Aarsland D; Larsen JP
    Neurology; 2005 Nov; 65(9):1436-41. PubMed ID: 16275832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Epidemiology and therapy of Parkinson disease in inpatient nursing homes].
    Evers S; Obladen M
    Z Gerontol; 1994; 27(4):270-5. PubMed ID: 7975818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The AMC Linear Disability Score in patients with newly diagnosed Parkinson disease.
    Weisscher N; Post B; de Haan RJ; Glas CA; Speelman JD; Vermeulen M
    Neurology; 2007 Dec; 69(23):2155-61. PubMed ID: 18056579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical therapy in Parkinson's disease: an open long-term rehabilitation trial.
    Pellecchia MT; Grasso A; Biancardi LG; Squillante M; Bonavita V; Barone P
    J Neurol; 2004 May; 251(5):595-8. PubMed ID: 15164194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study.
    Pedersen KF; Larsen JP; Alves G; Aarsland D
    Parkinsonism Relat Disord; 2009 May; 15(4):295-9. PubMed ID: 18801696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale.
    Louis ED; Lynch T; Marder K; Fahn S
    Mov Disord; 1996 Mar; 11(2):185-92. PubMed ID: 8684390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Speech disorders in Parkinson patients].
    Kerschan K; Pankl W; Auff E
    Wien Klin Wochenschr; 1998 Apr; 110(8):279-86. PubMed ID: 9615959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memory and executive function impairment predict dementia in Parkinson's disease.
    Levy G; Jacobs DM; Tang MX; Côté LJ; Louis ED; Alfaro B; Mejia H; Stern Y; Marder K
    Mov Disord; 2002 Nov; 17(6):1221-6. PubMed ID: 12465060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychometric properties of the Unified Parkinson's Disease Rating Scale and of the Short Parkinson's Evaluation Scale.
    Martignoni E; Franchignoni F; Pasetti C; Ferriero G; Picco D
    Neurol Sci; 2003 Oct; 24(3):190-1. PubMed ID: 14598081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.